Clinical Value and Mechanism Exploration of Serum miR-379 in Obesity-Polycystic Ovary Syndrome

Figures & data

Table 1 Clinical Characteristics and Sociodemographic Characteristics of PCOS Patients and Healthy People

	Healthy Group (n = 46)	Obesity-POCS Group (n = 93)	Non-Obesity PCOS Group (n = 31)	P value
				P1	P2	P3
Age (years)	27.50 ± 3.25	27.32 ± 3.24	27.52 ± 3.27	0.753	0.983	0.766
BMI (kg/m^2)	23.52 ± 2.04	27.74 ± 3.65	24.26 ± 2.29	<0.001	0.140	<0.001
FSH (U/L)	5.25 ± 0.93	3.07 ± 0.74	3.28 ± 0.77	<0.001	<0.001	0.184
LH (mIU/mL)	5.62 ± 1.14	13.15 ± 1.72	12.02 ± 1.22	<0.001	<0.001	0.001
E2 (pmmol/L)	196.43 ± 13.43	198.34 ± 6.39	197.97 ± 4.14	0.258	0.540	0.760
bP (nmol/L)	2.03 ±0.59	2.09 ± 0.33	2.03 ± 0.34	0.465	0.988	0.389
bT (nmol/L)	1.65 ± 0.35	1.95 ± 0.27	1.86 ± 0.50	<0.001	0.025	0.198
FINS (uIU/mL)	7.88 ±0.58	23.34 ± 1.55	10.16 ± 1.39	<0.001	<0.001	<0.001
Glu (mmol/L)	4.84 ± 0.63	4.78 ± 0.75	4.80 ± 0.79	0.8624	0.789	0.901
HOMA-IR	1.70 ± 0.25	4.96 ± 0.87	2.17 ± 0.50	<0.001	<0.001	<0.001

Notes: P1, obese PCOS group vs Control group; P2, non-obese PCOS group vs Control group; P3, obsess PCOS group vs non-obese PCOS group. Date was presented as mean ± SD.

Abbreviations: BMI, body-mass index; FSH, follicle-stimulating hormone; LH, luteinizing hormone; E2, estradiol; BP, progesterone; Glu, glucose; bT, bioavailable testosterone; HOMA-IR, homeostasis model assessment of insulin resistance; FINS, fasting plasma insulin.

Table 2 Correlation Between miR-379 Levels and Clinical Features in Obesity Patients

Parameters	Cases No. (n = 93)	miR-379 Expression		P
		Low (n = 44)	High (n = 49)
BMI (kg/m^2)				0.024
< 28	52	30	22
≥ 28	41	14	27
FSH (U/L)				0.186
< 3.1	49	20	29
≥ 3.1	44	24	20
bT (nmol/L)				< 0.001
< 2	52	33	19
≥ 2	41	11	30
FINS (uIU/mL)				0.393
< 23	38	20	18
≥ 23	55	24	31
HOMA-IR				0.014
< 5	51	30	21
≥ 5	42	14	28

Abbreviations: BMI, body-mass index; FSH, follicle-stimulating hormone; bT, basic testosterone; IR, insulin resistance; FINS, fasting plasma insulin.

Figure 1 Elevated miR-379 is a potential diagnostic biomarker for obesity-PCOS. (A) The expression of miR-379 in three groups was detected by RT-qPCR. (B) ROC was conducted to analyze the diagnostic value of miR-379 in identifying obesity-PCOS patients from the healthy or non-obesity-PCOS group. ****P < 0.0001.

Table 3 Logsitic Employed to Analyze Risk Factors for the Development of Obesity PCOS

Characteristics	Multivariate Analysis
	HR	95% CI	P
miR-379	7.172	2.415–21.300	<0.001
BMI	7.362	2.441–22.202	<0.001
FSH	0.507	0.192–1.342	0.171
bT	0.556	0.211–1.460	0.233
HOMA-IR	0.573	0.216–1.517	0.262

Abbreviations: PCOS, polycystic ovary syndrome; BMI, body mass index; FSH, follicle-stimulating hormone; bT, bioavailable testosterone; HOMA-IR, homeostasis model assessment of insulin resistance.

Figure 2 SEMA3A is a target gene of miR-379 in obesity-PCOS. (A) Sequence fragment of SEMA3A bound to miR-379. (B) Dual luciferase reporter validates targeted binding between miR-379 and SEMA3A. (C) Expression of SEMA5A in the three groups was detected by RT-qPCR. (D) Correlation analysis between miR-379 and SEMA3A in obesity-PCOS patients. ****P < 0.0001; ***P < 0.001; **P < 0.01.

Figure 3 miR-379 affects the proliferation of KGN by regulating SEMA3A. (A) Effect of miR-379 inhibitor and si-SEMA3A on miR-379 levels in KGN detected by RT-qPCR. (B) Effect of miR-379 inhibitor and si-SEMA3A on SEMA3A levels in KGN detected by RT-qPCR. (C) CCK-8 assay was employed to examine the proliferation of KGN cells function of miR-375 and SEMA3A. ***P < 0.001,**P < 0.01.